Chrono Therapeutics secured $32 million in Series A funding the company will use to complete the development and clinical studies of its wearable SmartStop smoking cessation system.
Close to six years after promising up to $500 million to gain rights to Zurich-based Cytos Biotechnology's ($CYTN) smoking cessation vaccine, Novartis has handed back the rights to the treatment and written off its investment.
CN Creative has secured $3.1 million in new financing to fund final development work for its electronic inhaler nicotine replacement therapy device to help patients quit smoking. Advent Life Sciences
Last week, Selecta Biosciences, a 2011 Fierce 15 company, announced that it has started a Phase I trial of a synthetic nanoparticle vaccine for smoking cessation. The shot, called SEL-068, is
Boston-based Selecta Biosciences, a 2011 Fierce 15 winner, has kicked off a Phase I trial of nicotine vaccine SEL-068 for smoking cessation and relapse prevention. The company is touting its trial as
A little-known biotech company founded by a group that includes Rick Stewart, the former CEO at Amarin, and focused on a single development project finds itself in the spotlight this morning. Extab,
Building on new insights gained from the discovery of a biomarker that can be used to track individual differences for the rate at which nicotine breaks down in the body, a team of researchers at the
Switzerland's Cytos Biotechnology (CYTN) stock was punished on the news that it's anti-smoking vaccine failed to hit its primary endpoint in a Phase II trial. This endpoint was defined as a
As Somaxon waits for the FDA okay on insomnia treatment Silenor, the company has lined up funding for marketing and commercialization of the drug. The company inked a $15 million secured loan
The FDA has quietly engineered the biggest change-up in the way many clinical trials are designed since the early '90s. Developers working in a range of fields including obesity, epilepsy, smoking